Disease · EFO_0004888
post operative nausea and vomiting
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. post operative nausea and vomiting. Diseases, record EFO_0004888. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0004888
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Approval, for 9 of its 52 drugs, from DailyMed, EMA Human Drugs and FDA
- Open Targets
Drugs52
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ONDANSETRON | CHEMBL46 | Small molecule | Approval | DailyMed | 62 | 6 | 6 | Drugs and targets |
| AMISULPRIDE | CHEMBL243712 | Small molecule | Approval | FDA | 6 | 5 | 5 | Drugs and targets |
| APREPITANT | CHEMBL1471 | Small molecule | Approval | DailyMed and EMA Human Drugs | 6 | 2 | 2 | Drugs and targets |
| TRIMETHOBENZAMIDE HYDROCHLORIDE | CHEMBL1200887 | Small molecule | Approval | DailyMed | 12 | 0 | 0 | Drugs and targets |
| ONDANSETRON HYDROCHLORIDE | CHEMBL3186492 | Small molecule | Approval | DailyMed | 8 | 0 | 0 | Drugs and targets |
| METOCLOPRAMIDE HYDROCHLORIDE | CHEMBL1200940 | Small molecule | Approval | DailyMed | 4 | 0 | 0 | Drugs and targets |
| SCOPOLAMINE | CHEMBL569713 | Small molecule | Approval | DailyMed | 3 | 0 | 0 | Drugs and targets |
| DOLASETRON MESYLATE | CHEMBL2368924 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| PALONOSETRON HYDROCHLORIDE | CHEMBL1720 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
1 to 10 of 52
See all 52 drugsTargets114
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| HTR3A | 5-hydroxytryptamine receptor 3A | 10 | Serotonin (5-HT) receptor antagonist; Serotonin 3 (5-HT3) receptor antagonist; Serotonin 3a (5-HT3a) receptor antagonist | Approval | https://conductscience.org/library/genes/3359 | Drugs and targets |
| OPRM1 | Mu-type opioid receptor | 8 | Mu opioid receptor agonist; Opioid receptors; mu/kappa/delta agonist | Phase 2 | https://conductscience.org/library/genes/4988 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 6 | Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor | Phase 2 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| DRD2 | D(2) dopamine receptor | 5 | D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist; Dopamine D2 receptor antagonist; Dopamine receptors; D2 & D3 antagonist | Approval | https://conductscience.org/library/genes/1813 | Drugs and targets |
| GABRA1 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2556 | Drugs and targets |
| GABRA4 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2557 | Drugs and targets |
| GABRA5 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2558 | Drugs and targets |
| GABRA6 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator | Phase 1 | https://conductscience.org/library/genes/2559 | Drugs and targets |
1 to 10 of 114
See all 114 targetsTrials54
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02646566 | Study of APD421 as PONV Treatment (Prior Prophylaxis) | Phase 3 | 705 | 2018-12-19 | Postoperative Nausea and Vomiting | AMISULPRIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02449291 | Study of APD421 as PONV Treatment (no Prior Prophylaxis) | Phase 3 | 568 | 2018-12-19 | Postoperative Nausea and Vomiting | AMISULPRIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00967499 | Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU) | Phase 2 | 239 | 2021-01-11 | Postoperative Nausea and Vomiting | ONDANSETRON, PALONOSETRON | Its record names the disease | ClinicalTrials.gov |
| NCT01451762 | A Dose Ranging Effect of Preoperative Diphenhydramine on Postoperative Quality of Recovery After Ambulatory Surgery | Not applicable | 90 | 2014-03-14 | Surgery, Pain | DIPHENHYDRAMINE | Its record names the disease | ClinicalTrials.gov |
| NCT02597907 | Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant | Not applicable | 88 | 2017-04-25 | Postoperative Nausea and Vomiting | APREPITANT, PALONOSETRON, RAMOSETRON | Its record names the disease | ClinicalTrials.gov |
| NCT02882854 | Guanfacine for PONV and Pain After Sinus Surgery | Not applicable | 84 | 2019-01-03 | Postoperative Nausea and Vomiting, Pain, Postoperative | GUANFACINE | Its record names the disease | ClinicalTrials.gov |
| NCT07480785 | TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients | Not applicable | 780 | Uterine Fibroids (Leiomyoma), Ovarian Tumors, Gallstones | DEXAMETHASONE, DROPERIDOL, PALONOSETRON | Its record names the disease | ClinicalTrials.gov | |
| NCT06810882 | Intravenous Versus Perineural Ondansetron for Laparoscopic Sleeve Gastrectomy | Not applicable | 482 | Ondansetron, Laparoscopic, Gastrectomy | ONDANSETRON | Its record names the disease | ClinicalTrials.gov | |
| NCT05280743 | Precision Opioid Care After Cesarean Delivery (PRECISE-CD) | 341 | Cesarean Section Complications, Opioid Use | OXYCODONE | Its record names the disease | ClinicalTrials.gov | ||
| NCT00695487 | Does Intravenous Cannabis Reduce Postoperative Nausea and Vomiting (PONV)? | Not applicable | 320 | Nausea, Vomiting | DRONABINOL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 54
See all 54 trialsComparisons in its trials7
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Palonosetron vs Ondansetron: deaths from any cause | 0 of 48 | 0 of 50 | 98 | NCT00967499 | Trial comparisons |
| Palonosetron vs Ondansetron: serious adverse events | 6 of 48 | 8 of 50 | 98 | NCT00967499 | Trial comparisons |
| Aprepitant Plus Palonosetron vs Aprepitant Plus Ramosetron: The Incidence of Postoperative Nausea and Vomiting | 5 of 44 | 18 of 44 | 88 | NCT02597907 | Trial comparisons |
| Aprepitant Plus Palonosetron vs Aprepitant Plus Ramosetron: deaths from any cause | 0 of 44 | 0 of 44 | 88 | NCT02597907 | Trial comparisons |
| Aprepitant Plus Palonosetron vs Aprepitant Plus Ramosetron: serious adverse events | 0 of 44 | 0 of 44 | 88 | NCT02597907 | Trial comparisons |
| Guanfacine vs Placebo: deaths from any cause | 0 of 40 | 0 of 44 | 84 | NCT02882854 | Trial comparisons |
| Guanfacine vs Placebo: serious adverse events | 0 of 40 | 0 of 44 | 84 | NCT02882854 | Trial comparisons |
Papers from its trials125
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0004888
GET https://conductscience.org/api/diseases/v1/EFO_0004888/drugs?page=2